Rethinking cannabinoid-based medication.

Our Focus

• CHILAM MONTHLYRESEARCH & DEVELOPMENT

  Female pain is a heavily underserved market with a clear unmet medical need.

  1 in 10 females currently suffer from endometriosis, a crippling chronic condition.

  Our team of scientists and experienced pharmaceutical specialists are leveraging patient research and clinical data to develop a pharmaceutical cannabinoid-based solution.

  Our research and development commenced in 2021 with the aim to develop a product and technology driven offering to dramatically enhance the quality of life for patients globally; allowing them to live a better, more successful life.

• CHILAM PHARMEU GMP EXTRACTION & FORMULATION

  Our green powered facility in Europe has been designed to produce unrivaled EU GMP trusted cannabinoid-based medicine.

  We are focused on the extraction, research and development and formulation of wholesale and white-label medicinal Active Pharmaceutical Ingredients.

  Our ethos in production is net positive. To thrive and grow as a company we responsibly produce products, creating value for our customers and our local and global communities.

About us

PEOPLE. THE FOUNDATION OF OUR SUCCESS.

Chilam is a UK based, fully licenced life science development company with operations in Europe.

The patient is at the heart of what we do, everyday. We bring together leading-edge science and research to redefine our core areas of focus and drastically improve patient communities around the world.

Chilam’s Board and Strategic Advisors have extensive knowledge in establishing, growing and scaling globally recognised companies, in the pharmaceutical, regulatory, technology and industry.

Our Leadership and Management team value expertise, along with capability. Chilam brings together a team of diverse minds who drive each other to create change and deliver innovation. Our accomplishments to date are a result of our diversity.